Hikma Pharmaceuticals Plc

As of June 30, 2026, Hikma Pharmaceuticals plc. carries a market capitalization of 4.23B, placing it among publicly traded companies globally. Its enterprise value stands at 5.92B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hikma Pharmaceuticals plc.'s next confirmed earnings release is scheduled for February 25, 2027.

As of June 30, 2026, Hikma Pharmaceuticals plc. has 210.44M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Hikma Pharmaceuticals plc. maintains a current ratio of 1.98, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 19, 2026, Hikma Pharmaceuticals plc.'s stock has declined approximately 7.67% over the past 52 weeks. The 50-day moving average sits at 20.15, while the 200-day moving average is 22.62.

As of June 30, 2026, Hikma Pharmaceuticals plc. holds 289.00M in cash and equivalents against 1.96B in total debt, resulting in a net debt position of 1.61B. Total book value stands at 2.52B, with working capital of 1.36B providing operational flexibility.